

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-0153US1</b>	Application No. <b>10/551,504</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Hiroyuki Tsunoda et al.</b>		
		Filing Date <b>September 29, 2005</b>	Group Art Unit <b>1647</b>	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2005/0130224	06/16/2005	Saito et al.			
	2	2007/0281327	12/06/2007	Nakano et al.			
	3	2008/0206229	08/28/2008	Ono et al.			
	4	2008/0274110	11/06/2008	Ozaki et al.			
	5	7,262,278	08/28/2007	Tawara et al.			

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes      No
	6	EP 1561759	08/10/2005	EPO			
	7	EP 1712565	10/18/2006	EPO			
	8	EP 1 327 680 A1	07/16/2003	EPO			
	9	EP 1369431 A1	12/10/2003	EPO			
	10	EP 1757686	02/28/2007	EPO			
	11	JP11-500916	01/26/1999	Japan			Abstract only
	12	JP 2004-0866862	03/18/2004	Japan			Abstract only
	13	WO 96/26648	09/06/1996	WIPO			
	14	WO 03/107218	12/24/2003	WIPO			Abstract only
	15	WO 05/056602	06/23/2005	WIPO			Abstract only
	16	WO 05/056603	06/23/2005	WIPO			Abstract only
	17	WO 05/056605	06/23/2005	WIPO			Abstract only
	18	WO 05/056798	06/23/2005	WIPO			Abstract only
	19	WO 05/100560	10/27/2005	WIPO			Abstract only

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	16	Burrone et al., "Stimulation of HLA-A,B,C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets," <i>The EMBO Journal</i> , 4(11):2855-2860 (1985)
	17	Cangemi et al., "IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome," <i>International Immunology</i> , 15(12):1415-1421 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-0153US1</b>	Application No. <b>10/551,504</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Hiroyuki Tsunoda et al.</b>	
		Filing Date <b>September 29, 2005</b>	Group Art Unit <b>1647</b>

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	18	CAPLUS Accession Number 2005:547624, 2 pages (2008)
	19	DeJonge et al., "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-DC3 x anti-idiotype) induces long term survival of the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161(3):1454-1461 (1998)
	20	Kriangkum et al., "Bispecific and bifunctional single chain recombinant antibodies," <i>Biomol. Eng.</i> , 18(2):31-40 (2001)
	21	Kumar et al., "The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C. Mutational analysis and naturally occurring variants," <i>J. Biol. Chem.</i> , 276(27):24971-2497 (2001)
	22	Mack et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(15):7021-7025 (1995)
	23	Mallender et al., "Construction, expression and activity of a bivalent bispecific single-chain antibody," <i>J. Biol. Chem.</i> , 269(1):199-206 (1994)
	24	McInnes and Schett, "Cytokines in the pathogenesis of rheumatoid arthritis," <i>Nature Reviews/Immunology</i> , 7:429-442 (2007)
	25	Sal-man et al., "Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive monodimer dissociation and heterodimer association <i>n vivo</i> ," <i>Biochem. J.</i> , 385(1):29-36 (2005)
	26	Scott, "The Problem with Potency," <i>Nature Biotechnology</i> , 23(9):1037-1039 (2005)
	27	Seikomoto et al., "A Single-Chain Fv Diabody Against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment," <i>Cancer Res.</i> , 67(3):1184-1192 (2007)
	28	Sekimoto et al., "Eradication of Human Myeloma Cells by a Recombinant HLA Class I-Specific Single Chain Fv Diabody," <i>Blood</i> , 102:932a, XP009106629 (Abstract #3469) (November 2003) [Abstract of the American Society of Hematology 45 <sup>th</sup> Annual Meeting, December 6-9, 2003, San Diego, California]
Ozaki	29	Sekimoto et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, XP002987122 (Abstract #3474) (November 2003) [Abstract of the American Society of Hematology 45 <sup>th</sup> Annual Meeting, December 6-9, 2003, San Diego, California]
	30	Stein et al., "Characterization of humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab," <i>Blood</i> , 108(8):2736-2744 (2006)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature  <b>/Lorraine Spector/</b>	Date Considered  <b>03/23/2009</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	